Investigational acasunlimab (duobody® -pd-l1x4-1bb) in combination with pembrolizumab demonstrates meaningful clinical activity in phase 2 trial in patients with previously treated metastatic non-small cell lung cancer (mnsclc)

Copenhagen, denmark, and mainz, germany, june 1, 2024 — genmab a/s (nasdaq: gmab, “genmab”) and biontech se (nasdaq: bntx, “biontech”) today announced initial data from the ongoing phase 2 trial ( nct05117242 ) evaluating acasunlimab (duobody-pd-l1x4-1bb), an investigational bispecific antibody also known as gen1046/bnt311, as monotherapy and in combination with pembrolizumab in patients with pd-l(1)-positive metastatic non-small cell lung cancer (“mnsclc”) who had disease progression following one or more prior lines of anti-pd(l)1-containing treatment. the results showed a 12-month overall survival (“os”) rate of 69%, a median overall survival (“mos”) of 17.5 months, and a 30% overall response rate (“orr”) (confirmed orr 17%) at the time of data cut-off in patients treated with the combination of acasunlimab and pembrolizumab every six weeks. the findings were presented at the 2024 american society of clinical oncology (“asco”) annual meeting held in chicago, il from may 31-june 4, 2024.
NDAQ Ratings Summary
NDAQ Quant Ranking